NCT05640453

Pregabalin Versus Dexmedetomidine for Delirium Treatment After Coronary Artery Bypass Grafting

Pregabalin Versus Dexmedetomidine for Delirium Treatment After Coronary Artery Bypass Grafting: A Randomized Double-Blind Trial

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 65 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to determine the effect of pregabalin versus dexmedetomidine on the treatment and lasting duration of delirium in fast tracking elderly patients after Coronary Artery Bypass Grafting.

Detailed description

Delirium is an acute brain disorder that involves changes in consciousness, attention, cognition, and perception.The incidence of postoperative delirium (POD) is high among patients undergoing cardiac surgery, ranging from 20 to 50%, and the risk is even higher in the elderly.

Conditions

• Pregabalin
• Delirium Treatment
• Coronary Artery Bypass Grafting
• Dexmedetomidine

Interventions

Type	Name	Description
DRUG	Pregabalin	Patients will receive pregabalin capsules (75 mg) every 12 h for 24 hours by nasogastric tube.
DRUG	Dexmedetomidine	Patients will receive a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min)

Timeline

• Start date: 2022-12-15
• Primary completion: 2026-05-15
• Completion: 2026-05-15
• First posted: 2022-12-07
• Last updated: 2025-06-25

Locations

1 site across 1 country: Egypt